Protective Effect of KTM on Streptozotocin-Induced Diabetic Symptoms and Their Potential Mechanisms in Rats

Baozhong Diao¹, Weirong Jin¹*, Feng E. Zhang², Wenzhou Zhang³

¹Department of Formulation Branch, Liaocheng People's Hospital, Liaocheng, China
²Department of Emergency, Liaocheng People's Hospital, Liaocheng, China
³Department of Pharmacy, Liaocheng People's Hospital, Liaocheng, China

Email address: lesmyyjwr@163.com (Weirong Jin)
*Corresponding author

To cite this article:
doi: 10.11648/j.ajcem.20180603.11

Received: March 26, 2018; Accepted: April 12, 2018; Published: May 24, 2018

Abstract: objective: The present study aimed to evaluate the therapeutic effects of ketangmin (KTM) on streptozotocin-(STZ) induced diabetic symptoms and their potential mechanisms. Methods: The effect of KTM on body weight, blood glucose, damaged pancreatic β-cells, oxidative stresses, proinflammatory cytokines, and glucose metabolizing enzymes in liver was studied. Results: The results show that administration of KTM can restore abnormal oxidative indices near normal levels. The STZ-damaged pancreatic β-cells of the rats were partly recovered gradually after the mice were administered with KTM 6 weeks later. Therefore, we may assume that KTM is effective in the protection of STZ-induced diabetic rats and KTM may be of use as antihyperglycemic agent.

Keywords: Ketangmin (KTM), Streptozotocin-Induced Diabetic Symptoms, Potential Mechanisms

1. Introduction

Diabetes mellitus is linked to a series of cardiovascular and micro vascular changes that can be manifest as a wide range of complications [1]. Diabetes mellitus is a metabolic disorder affecting carbohydrate, fat, and protein metabolism. Long-standing diabetics is prone to various complications which include cardiac, kidney, eye problems and pancreatic cancer [2, 3]. More effective and safer treatment modalities for diabetes mellitus have to be investigated. KTM is developed by our hospital, new kind antidiabetic preparation. More than 10 years of clinical applications. For diabetes has a good effect of prevention and control of diabetes and complication. Up to now, however, no detailed investigation has been carried out on the effective constituents of KTM for an-ihyperglycemic activities. Today, calling for return to natural therapy to treat diabetes stronger and stronger [4].

In the present study, the purpose is to focus on theKTM for alleviating the diabetessmellitus.

2. Materials and Methods

2.1. KTM Composition

KTM composition is as follows: Astragalus membranaceus (Fisch.) Bge. var. mongholicus (Bge). Hsiao (150g); Atractylodes macrocephala Koidz (150g); Trichosanthes kirilowii Maxim. (300g); Rehmannia glutinosa Libosch (300g); Rehmannia glutinosa Libosch (300g); Dioscorea opposita Thunb (300g) eleven herbs Etc.

Above 8 herbs were heated and boiled in water twice: first, for two hours and, second, for 1.5 hours. Then follow these steps: the merger decoction, filtration, the filtrate being concentrated to about 800 mL, adding water to 1000 mL, mixing, packaging, and sterilization.

2.2. Animals

Healthy male adult Wistar rats (2 months old and weighing 200 ± 20g) were used in the study. This study was carried out...
in accordance with the Guide for the Care and Use of Laboratory Animals. Care was taken to minimize discomfort, distress, and pain to animals. The protocols were approved by the Hospital Ethics Committee. Experimental diabetes was induced by intrapulmonary (i.p.) injection with a freshly prepared solution of STZ (Sigma, USA) dissolved in citrate buffer (pH 4.5) at the dose of 35 mg/kg body weight. Only rats with blood glucose concentration more than 240 mg/dL were considered diabetic and utilized for the study. Glucose level was assessed by using enzymatic glucose oxidase peroxidase commercially available kit method. 72 h after STZ induction. The rats with blood glucose concentration more than 240 mg/dL were considered diabetic and used for the study.

2.3. Treatment Schedule and Experimental Protocol

Protocol. Forty hypoglycemic rats were selected and allocated equally into 4 groups and administered orally Saline, KTM (10 g/kg/d), KTM (20 mg/kg/d), and KTM (30 mg/kg/d), respectively. The other 10 normal rats were administered orally with the saline and used as the control group.

Body weight of all animals was recorded on 0, 1st, 2nd, 3rd, 4th, 5th, and 6th week of treatment. Blood of all animals was collected through retro orbital route initially and on 6th week of treatment to measure the serum glucose levels. Then, the rats were killed. The blood sample had a right to clot for 20 minutes at refrigerator temperature. The blood samples were then shifted to clean centrifuge tubes. Lithium heparin was in addition to obtain plasma. The withdrawn blood was isolated by centrifugation at 4000 rpm for 10 minutes to obtain serum. The serum was stored in a freezer until analysis. The liver was dissected out for the measurement of IL-1β and TNF-a. The pancreas was reserved for pathological histology using hematoxylin and eosin (H&E) staining.

2.4. Measurement of IL-1β and TNF-a Level in Liver

The liver was dissected out for the measurement of hepatic glycogen. The liver TNF-a and IL-1β were measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Shanghai Jinma Biological Technology Inc., China) following the manufacturer's instruction.

2.5. Measurement of Lipid Profile

Total cholesterol (TC), triglycerides (TAG), low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol was determined in the serum samples using commercially available kits (Shanghai Jinma Biological Technology Inc., China).

2.6. Measurement of Glucose Metabolizing Enzymes

The liver homogenate was used to assess metabolism enzymes. Glutamic oxaloacetate transaminase (GOT), glutamate pelvic transaminase (GPT), and lactate dehydrogenase (LDH) were measured using commercially available kits (Shanghai Jinma Biological Technology, Inc., China).

2.7. Estimation of the Total Antioxidant Activity

Total antioxidant status (TAOS) of hepatic tissue was determined by the way introduced by Laight et al. [9]. The increase in absorbance at 405nm was measured by using a microplate reader (Shanghai Xunda Medical Technology, Inc., China).

2.8. Statistical Analysis

All data were analyzed by a one-way analysis of variance, and the differences between means were established by Newman-Keuls test. The datum represents means and standard deviations. The significant level of 5% (P<0.05) was considered to be the minimum acceptable probability for the difference between the means.

3. Results and Discussion

The objective of this study was to investigate whether the polysaccharides from 1. Obli-quus (KTM) could produce hypoglycemic activity in STZ-induced diabetic rats. STZ is an antibiotic extracted from Streptomyces chromosomes and is diabetogenic due to a selective cytotoxic action upon pancreaticβ-cell [5]. In the present investigation, STZ injected rats exhibit clinic pathological features including biochemical, oxidative, and metabolic changes. These changes were halted in KTM treated animals. Many studies have shown a glycemia and decreased body association between hyper weight of diabetic animals [6]. As showed in Figure 1, the STZ-treated animals had significantly reduced body weight than the control rats (P<0.01). When compared with TZ-treated animals, the body weight gains were significantly increased in groups of KTM treated animals (P<0.05; P<0.01) in a dose-dependent manner. STZ in the experimental diabetic model leads to defective glucose oxidation and causes hyperglycemia [7]. Our study is consistent with this report. The blood glucose level in normal rats remained constant for six weeks and was signifi-cantly lower than those of streptozotocininduced diabetic rats (Table 1). Upon treatment with KTM for six weeks, the blood glucose levels of all diabetic rats were mar-kedly diminished in a dose-dependent manner, suggesting that KTM is a potent thera-apeutic agent against diabetes.
Table 1. Effect of KTM on blood glucose levels in STZ-hyperglycemic rats (n=10).

<table>
<thead>
<tr>
<th>Different groups</th>
<th>Blood glucose (mmol/L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>5.9±1.2</td>
</tr>
<tr>
<td>STZ</td>
<td>22.2±2.2</td>
</tr>
<tr>
<td>KTM30</td>
<td>10.1±3.2*</td>
</tr>
<tr>
<td>KTM20</td>
<td>15.5±2.0*</td>
</tr>
<tr>
<td>KTM10</td>
<td>18.6±3.0*</td>
</tr>
</tbody>
</table>

Mark: Values are means±SEM; n=10.*P<0.05 versus STZ group.

Hypoglycemic mechanisms of many polysaccharides are closely related to their antioxidant activity [8]. Hence, it is plausible that the hypoglycemic effect of KTM may be explained by the effect of alleviating oxidative stress. The TAOS is a sign of O2- and other oxidant species. We measured TAOS activity as an indirect indication of the formation of O2- and other oxidant species. Results of hepatic TAOS are shown in Table 2. The STZ treatment increased TAOS. TAOS in the KTM-20- and KTM-30-treated groups were significantly lower than those in the STZ-treated group (P<0.01, rep.).

Table 2. Effect of KTM on TAOS activity (µM-ascorbate). (n=10).

<table>
<thead>
<tr>
<th>Groups</th>
<th>TAOS activity (µM-ascorbate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STZ</td>
<td>82.00±3.31</td>
</tr>
<tr>
<td>KTM (10mg)</td>
<td>68.3±2.39*</td>
</tr>
<tr>
<td>KTM (20mg)</td>
<td>60.02±1.32*</td>
</tr>
<tr>
<td>KTM (30mg)</td>
<td>51.01±2.20*</td>
</tr>
<tr>
<td>Control group</td>
<td>28.04±1.02</td>
</tr>
</tbody>
</table>

Mark: Values are means±SEM; n=10.*P<0.01 versus STZ group.

It has been observed that over 75% of premature deaths in diabetes are related to coronary artery disease caused by abnormal lipid metabolism, which often leads to altered lipid profile of the victim [9]. Lipid peroxidation is part of the characteristic features of chronic diabetes. The increased free radicals produced may react with polyunsaturated fatty acids in cell membranes leading to lipid peroxidation. It will, in turn, result in the elevated production of free radicals [10]. In the present experiment, significantly increased lipid peroxidation products were observed in STZ-induced diabetic rats. Treated with KTM-20 and KTM-30 for 6 weeks, LDL level was reduced (P<0.05), whereas HDL cholesterol was raised (P<0.05) (Table 3). These results further confirm that there is a strong correlation between oxidative stress and diabetes occurrence.

Table 3. Effect of KTM on changes in the levels of serum lipid profile. (n=10).

<table>
<thead>
<tr>
<th>Lipid profile (mmol/L)</th>
<th>Cholesterol</th>
<th>Triglycerides</th>
<th>LPO</th>
<th>HDL</th>
<th>LDL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>4.30±0.22</td>
<td>0.81±0.17</td>
<td>8.59±0.11</td>
<td>0.72±0.63</td>
<td>0.28±0.01</td>
</tr>
<tr>
<td>STZ</td>
<td>10.55±1.01</td>
<td>2.22±0.91</td>
<td>15.2±1.30</td>
<td>1.34±0.21</td>
<td>0.70±0.04</td>
</tr>
<tr>
<td>KTM10</td>
<td>8.31±1.60*</td>
<td>0.99±0.05*</td>
<td>9.29±0.33*</td>
<td>0.82±0.07*</td>
<td>0.37±0.31*</td>
</tr>
<tr>
<td>KTM20</td>
<td>7.31±0.38*</td>
<td>0.81±0.03*</td>
<td>8.86±0.01*</td>
<td>0.86±0.05*</td>
<td>0.32±0.22*</td>
</tr>
<tr>
<td>KTM30</td>
<td>4.30±0.21*</td>
<td>0.78±0.07*</td>
<td>7.39±1.22*</td>
<td>0.72±0.03*</td>
<td>0.23±0.04*</td>
</tr>
</tbody>
</table>

Mark: Values are shown as means±SEM; *P<0.01 versus STZ group.

A chronic inflammation may play a role in the pathogenesis of metabolic disorders [13, 14]. Prospective studies have identified proinflammatory cytokines as predictors of diabetes [15]. TNF-α was the first proinflammatory cytokine implicated in pathogenesis of obesity-related insulin resistance and diabetes [16] and studies conducted with IL-1β antagonism beneficial effects on glycine hemoglobin and β-cell function [17]. Therefore, the effect of KTM on TNF-α and IL-1β production was determined by ELISA. In comparison to STZ group (Figure 2), treatment with KTM-30 led to a marked decrease in IL-1β levels (P<0.05). In addition, KTM-30 suppressed STZ-induced TNF-α production (P<0.05) (Figure 3).

Table 4. Effect of KTM on GOT, GPT, and LDH. (Unit: L⁻¹, n=10).

<table>
<thead>
<tr>
<th>Group</th>
<th>GOT</th>
<th>GPT</th>
<th>LDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>66.0±2.27</td>
<td>79.8±0.87</td>
<td>48.6±0.11</td>
</tr>
<tr>
<td>STZ</td>
<td>159.2±1.01</td>
<td>288.2±0.91</td>
<td>317.2±3.30</td>
</tr>
<tr>
<td>KTM10</td>
<td>155.1±1.60*</td>
<td>184.9±0.05*</td>
<td>299.8±0.33*</td>
</tr>
<tr>
<td>KTM20</td>
<td>129.1±0.38*</td>
<td>103.7±0.03*</td>
<td>186.4±0.01*</td>
</tr>
<tr>
<td>KTM30</td>
<td>67.1±1.21**</td>
<td>80.8±0.07**</td>
<td>77.3±1.22**</td>
</tr>
</tbody>
</table>

Mark: Values are shown as means±SEM; *P<0.01 versus STZ group.

A chronic inflammation may play a role in the pathogenesis of metabolic disorders [13, 14]. Prospective studies have identified proinflammatory cytokines as predictors of diabetes [15]. TNF-α was the first proinflammatory cytokine implicated in pathogenesis of obesity-related insulin resistance and diabetes [16] and studies conducted with IL-1β antagonism beneficial effects on glycine hemoglobin and β-cell function [17]. Therefore, the effect of KTM on TNF-α and IL-1β production was determined by ELISA. In comparison to STZ group (Figure 2), treatment with KTM-30 led to a marked decrease in IL-1β levels (P<0.05). In addition, KTM-30 suppressed STZ-induced TNF-α production (P<0.05) (Figure 3).
STZ is a compound commonly used to cause diabetes in rodents. The mode of its action is mediated through the induction of severe damages to the β-cells [18]. The protective effect of KTM against the damages to β-cells induced by STZ toxicity was studied. Selective destruction of pancreatic β-cells by STZ in the experimental diabetic model was observed (Figure 4(b)). We observed focal necrosis, congestion in central vein, and infiltration of lymphocytes in the pancreas of STZ. Such lesions were considerably diminished by KTM-30 (Figure 4(c)). Further, β-cells structure of the KTM rats appeared normal. This indicated that KTM could signify candy protects the β-cells from STZ-induced cell damage. This result expressed support for the therapeutic potential of KTM against diabetes. And KTM's antidiabetic mechanism is most likely achieved by activating dormant islet cell receptors.
In summary, we have demonstrated that KTM has therapeutic effects against diabetes via multiple pathways. It displays antioxidant actions, hyperlipidemia activity, and protects the pancreas from diabetes induced injuries in STZ-treated rats. Therefore, KTM may provide a valuable therapeutic option against diabetes.

Acknowledgements

This work was supported by Liaocheng People’s Hospital Pharmacy Department and Liaocheng project “Research on KTM development and quality standards”. There was no funding.

Conflict of Interest

The authors declare no financial or other conflicts of interest.

References


